Icotinib | CAS# 610798-31-7 | antineoplastic

MedKoo Cat#: 413263 | Name: Icotinib

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Icotinib is an oral, first-generation EGFR tyrosine kinase inhibitor (TKI) approved in China for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutations such as exon 19 deletions and L858R. It works by inhibiting EGFR autophosphorylation, thereby blocking downstream signaling pathways that promote cancer cell proliferation and survival. Icotinib has demonstrated potent bioactivity (IC₅₀ ≈ 5 nM) and comparable efficacy to gefitinib, with a more favorable safety profile.

Chemical Structure

Icotinib

CAS#610798-31-7 (free base)

Theoretical Analysis

MedKoo Cat#: 413263

Name: Icotinib

CAS#: 610798-31-7 (free base)

Chemical Formula: C22H21N3O4

Exact Mass: 391.1532

Molecular Weight: 391.43

Elemental Analysis: C, 67.51; H, 5.41; N, 10.74; O, 16.35

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 500.00	2 Weeks
50mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1204313-51-8 (HCl) 610798-31-7 (free base)

Synonym

Icotinib; Conmana; BPI2009; BPI 2009; BPI-2009

IUPAC/Chemical Name

(1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-

InChi Key

QQLKULDARVNMAL-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)

SMILES Code

C#CC1=CC(NC2=C3C=C(OCCOCCOCCO4)C4=CC3=NC=N2)=CC=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q.

In vitro activity:

Ten HCC (hepatocellular carcinoma) cell lines were selected to test their original EGFR-activation status and PDL1 protein level, and in vitro antiproliferation assays were also conducted to analyze the IC50 and further investigate the correlation between IC50 and protein level of phosphorylated EGFR and PDL1. Icotinib showed significant inhibitory effects only on HCC cell lines that had both higher p-EGFR and PDL1 protein level. Molecular mechanism study revealed that icotinib inhibited the phosphorylation of EGFR and PDL1 expression in cancer cells and activated apoptosis. Knocking down PDL1 significantly reduced the inhibitory effect of icotinib on HCC, and knocking in PDL1 increased the sensitivity of icotinib in HCC. These results suggest that icotinib has an inhibitory effect on a subgroup of HCC cells that have both higher p-EGFR and PDL1. Reference: Onco Targets Ther. 2018 Nov 21;11:8227-8237. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254541/

In vivo activity:

Huh7 cells were injected subcutaneously into the right limb, and when tumors had reached 100 mm3, the mice began to receive icotinib administration every 2 days. The whole treatment lasted 3 weeks. Tumor sizes in the control group increased significantly. Compared with the control group, tumor volumes in the icotinib treated group decreased dose-dependently, and the difference was statistically significant (Figure 6), which suggested that icotinib reduced sensitive HCC-tumor growth in vivo. Reference: Onco Targets Ther. 2018 Nov 21;11:8227-8237. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254541/

	Solvent	mg/mL	mM
Solubility
	DMSO	78.0	199.27
	DMSO:PBS (pH 7.2) (1:4)	0.3	0.64
	Ethanol	7.0	17.88

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 391.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Sun J, Jiang W, Tian D, Guo Q, Shen Z. Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression. Onco Targets Ther. 2018 Nov 21;11:8227-8237. doi: 10.2147/OTT.S179844. PMID: 30538492; PMCID: PMC6254541. 2. Zhang S, Fu Y, Wang D, Wang J. Icotinib enhances lung cancer cell radiosensitivity in vitro and in vivo by inhibiting MAPK/ERK and AKT activation. Clin Exp Pharmacol Physiol. 2018 May 16. doi: 10.1111/1440-1681.12966. Epub ahead of print. PMID: 29770473.

In vitro protocol:

In vivo protocol:

1: Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y. Icotinib versus gefitinib in previously treated advanced non- small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non- inferiority trial. Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13. PMID: 23948351. 2: Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. doi: 10.1093/annonc/mdx359. PMID: 28945850. 3: Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, Tan FL, Zhong W, Wu YL. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017 Sep;5(9):707-716. doi: 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19. PMID: 28734822. 4: Zhao Q, Cheng J, Chen P, Sun J, Guan S. Icotinib: efficacy in different solid tumors and gene mutations. Anticancer Drugs. 2020 Mar;31(3):205-210. doi: 10.1097/CAD.0000000000000861. PMID: 31934888. 5: Li X, Zhang L, Jiang D, Wang Y, Zang A, Ding C, Zhao M, Su W, Zhang Y, Zhong D, Wu J, Zhang C, An G, Hu X, Cheng G, Wang H, Li Y, He X, Liu J, Liang L, Ding L, Mao L, Zhang S. Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. Clin Cancer Res. 2020 Jul 1;26(13):3162-3171. doi: 10.1158/1078-0432.CCR-19-3064. Epub 2020 Feb 14. PMID: 32060099. 6: Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, Zhuang W, Zhang YB, Wang LP, Fang MY, Xu CW, Wang XJ, Lv TF, Song Y. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study. Cancer Sci. 2020 Feb;111(2):679-686. doi: 10.1111/cas.14277. Epub 2020 Jan 16. PMID: 31828849; PMCID: PMC7004544. 7: Zhou X, Hua D, Gao C, Zhang Y, Qiu L, Wang L. Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients. Oncol Lett. 2019 Oct;18(4):4153-4159. doi: 10.3892/ol.2019.10763. Epub 2019 Aug 16. PMID: 31516614; PMCID: PMC6732991. 8: Wang GH, Hu ZY. Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells. Math Biosci Eng. 2019 Aug 21;16(6):7707-7718. doi: 10.3934/mbe.2019386. PMID: 31698635. 9: Peng LY, Yu M, Yang MX, Liu P, Zhou H, Huang W, Kong H, Xie WP. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction. Am J Hypertens. 2020 Aug 4;33(8):775-783. doi: 10.1093/ajh/hpaa066. PMID: 32301965. 10: Guan YS, He Q, Li M. Icotinib: activity and clinical application in Chinese patients with lung cancer. Expert Opin Pharmacother. 2014 Apr;15(5):717-28. doi: 10.1517/14656566.2014.890183. Epub 2014 Mar 4. PMID: 24588695.